#新冠疫苗接種點地圖服務#A medical worker injects COVID-19 vaccine to an inoculator at the vaccination point of the Shandong Provincial Third Hospital in Jinan, east China's Shandong Province, Jan. 4, 2021. (Xinhua/Guo Xulei)
2021年1月4日，一名醫務工作者在中國東部山東省濟南市山東省第三醫院的接種點向接種者注射了COVID-19疫苗（新華社/郭旭磊）
BEIJING, Jan. 9 (Xinhua) -- China has administered more than 9 million doses of self-developed COVID-19 vaccines. A senior health official announced this at a press conference on Saturday.
新華社北京１月９日電中國已管理了超過９００萬劑自行研製的ＣＯＶＩＤ－１９疫苗。一位高級衛生官員在周六的新聞發布會上宣布了這一消息。
Starting Dec. 15, China officially launched the COVID-19 vaccination program for this winter-spring period targeting a number of key groups, including those engaged in handling imported cold-chain products, customs officers, medical workers, and people working in public transport and fresh markets.
從12月15日開始，中國在這個冬春期間正式啟動了COVID-19疫苗接種計劃，其對象是許多關鍵群體，包括從事進口冷鏈產品進口的人員，海關人員，醫務人員和從事公共運輸工作的人員和新鮮市場。
Since then, more than 7.5 million doses have been administered among these groups, said Zeng Yixin, deputy head of the National Health Commission (NHC).
國家衛生委員會（NHC）副主任曾義新說，自那時以來，已在這些人群中進行了超過750萬劑的給藥。
People wait in an observation area after receiving their COVID-19 vaccines at a temporary vaccination site in Haidian District of Beijing, capital of China, Jan. 6, 2021. (Xinhua/Ren Chao)
2021年1月6日，人們在中國首都北京海澱區的一個臨時疫苗接種點接受COVID-19疫苗後，在觀察區內等候。（新華社/任超）
With the previous 1.6 million doses targeting groups with high risks of infection, a total of over 9 million doses have been administered in China. It further proved the safety of self-developed COVID-19 vaccines, Zeng said.
以前的160萬劑疫苗針對的是高感染風險人群，因此在中國總共給藥了900萬劑以上。曾說，這進一步證明了自主研發的COVID-19疫苗的安全性。
Zeng said that China would vaccinate the eligible population as widely as possible and gradually build an immune barrier in the whole population to control the epidemic.
曾慶紅說，中國將為符合條件的人群儘可能地接種疫苗，並逐步在整個人群中建立免疫屏障，以控制該流行病。
The vaccination would be administered in the order of key groups, high-risk groups, and the general population as the vaccine's production capacity increases, he said.
他說，隨著疫苗生產能力的提高，疫苗將按關鍵人群，高危人群和普通人群的順序進行接種。
Zeng noted that China has a variety of measures in place to ensure safe vaccinations, including proper vaccination procedures, strict vaccinator training, vaccine recipient screening, adverse reaction monitoring, emergency treatment, and expert consultations on adverse reactions, Zeng said.
曾慶紅說，中國採取了各種措施來確保安全的疫苗接種，包括適當的疫苗接種程序，嚴格的疫苗接種人員培訓，疫苗接種者篩查，不良反應監測，緊急治療以及不良反應專家諮詢。
A medical worker asks about the physical condition of a man who is about to receive the COVID-19 vaccination at Jiangxi Provincial People's Hospital in Nanchang, capital of east China's Jiangxi Province, Jan. 4, 2021. (Xinhua/Peng Zhaozhi)
2021年1月4日，一名醫務人員在中國東部江西省省會南昌市江西省人民醫院詢問即將接受COVID-19疫苗接種的男子的身體狀況（新華社/彭兆志）
A total of 25,392 vaccination sites are available nationwide. Nearly 140,000 people have been vaccinated so far in north China's Hebei Province, said Cui Gang, an official with NHC's disease control department. He demanded efforts to speed up vaccination among key groups in the province as soon as possible.
全國共有25,392個疫苗接種點。NHC疾病控制部門的官員崔剛說，到目前為止，在中國北方的河北省已經有14萬人接受了疫苗接種。他要求儘快在全省重點人群中進行疫苗接種。
The NHC has organized experts to work out eight detailed plans to guide the vaccinations, from vaccine transportation and distribution to adverse reaction prevention, Cui said.
崔說，國家衛生委員會已組織專家制定了八項詳細計劃，以指導疫苗接種，從疫苗的運輸和分發到預防不良反應。
A traceability information system for the management of vaccines now operates in medical institutions at all levels, Cui added.
Cui補充說，用於疫苗管理的可追溯性信息系統現在在各級醫療機構中運行。
A medical worker shows the COVID-19 vaccine developed by Beijing Biological Products Institute Co., Ltd. at the health management center in Panyu District of Guangzhou City, south China's Guangdong Province, Jan. 6, 2021. (Xinhua/Xu Hongyi)
2021年1月6日，一名醫務人員在中國南方的廣東省廣州市番yu區衛生管理中心展示了北京生物製品研究院有限公司研製的COVID-19疫苗。（新華社/徐宏義）
Wang Huaqing, an expert from the Chinese Center for Disease Control and Prevention, said vaccination monitoring showed that most of the adverse reactions, including rashes and allergic reactions, are mild. Approximately one in a million encountered relatively serious adverse reactions.
中國疾病預防控制中心的專家王華慶說，疫苗接種監測顯示，大多數不良反應，包括皮疹和過敏反應，都是輕度的。大約百萬分之一的人遇到了相對嚴重的不良反應。
COVID-19 vaccinations costs, including vaccine expenses and inoculation fees, would be covered by medical insurance funds and government fiscal, rather than individuals, said Li Tao, deputy director of the National Healthcare Security Administration.
國家醫療安全局副局長李濤說，COVID-19疫苗接種費用，包括疫苗費用和接種費用，將由醫療保險基金和政府財政而非個人承擔。
He also noted that the administration's disbursement on COVID-19 vaccines would not affect the current revenue and expenditure of medical insurance funds or residents' medical treatment.
他還指出，政府對COVID-19疫苗的撥款不會影響當前醫療保險基金或居民醫療收入和支出。
Staff members work at a COVID-19 vaccine packaging plant of Sinovac Research and Development Co., Ltd. in Beijing, capital of China, Jan. 6, 2021. (Xinhua/Zhang Yuwei)
2021年1月6日，工作人員在位於中國首都北京的Sinovac Research and Development Co.，Ltd.的COVID-19疫苗包裝廠工作。（新華社/張宇偉）
Zheng Zhongwei, head of the working group for vaccine development under the State Council joint prevention and control mechanism against COVID-19, said China has promised to make its COVID-19 vaccine a global public good when available, contributing to vaccine accessibility and affordability in developing countries.
國務院針對COVID-19的聯合預防和控制機制下的疫苗開發工作組負責人鄭中偉表示，中國已承諾將COVID-19疫苗在可獲得的情況下成為全球公共物品，從而為疫苗的可及性和可負擔性做出貢獻。發展中國家。
China's vaccine enterprises took consideration of this promise when laying out the vaccine production capacity, Zheng said.
鄭說，中國的疫苗企業在規劃疫苗生產能力時考慮了這一承諾。